During the past decade, Institute for Asthma and Allergy conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 16 clinical trials were completed, i.e. on average, 88.9% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 5 clinical trials were completed. i.e. 55.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute for Asthma and Allergy" #1 sponsor was "Shire" with 16 trials, followed by "Meda Pharmaceuticals" with 4 trials sponsored, "CSL Behring" with 2 trials sponsored, "Grifols Therapeutics LLC" with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute for Asthma and Allergy" #1 collaborator was "Sanofi" with 1 trials as a collaborator, "Shire Human Genetic Therapies, Inc." with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Institute for Asthma and Allergy" are "Hereditary Angioedema" (12 trials), "Hereditary Angioedema (HAE)" (9 trials), "Asthma" (2 trials), "Chronic Rhinosinusitis" (2 trials) and "Nasal Polyps" (2 trials). Many other conditions were trialed in "Institute for Asthma and Allergy" in a lesser frequency.

Most popular intervention types in "Institute for Asthma and Allergy" are "Drug" (30 trials), "Biological" (14 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "C1 esterase inhibitor [human] (C1INH-nf)" (5 trials), "ecallantide" (4 trials), "Omalizumab" (3 trials) and "0.15% azelastine hydrochloride" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institute for Asthma and Allergy" are 40 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Institute for Asthma and Allergy". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in Institute for Asthma and Allergy, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institute for Asthma and Allergy, 3 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 0 trials that are defined as “Not Applicable".